FDA 510(k) vs EU MDR: Key Differences for Medical Device Manufacturers

For medical device manufacturers looking to sell in both the United States and Europe, understanding the fundamental differences between the FDA 510(k) pathway and the EU MDR conformity assessment process is essential. While both aim to ensure device safety and effectiveness, they differ significantly in philosophy, requirements, and process.

Overview: Two Different Philosophies

The FDA 510(k) pathway is based on the concept of substantial equivalence: demonstrating that your device is as safe and effective as an already-marketed predicate device. It is a premarket notification, not an approval.

The EU MDR framework is based on essential requirements conformity: demonstrating that your device meets the General Safety and Performance Requirements (GSPR) in Annex I of the regulation. CE marking is achieved through a conformity assessment involving (for most classes) a Notified Body.

Side-by-Side Comparison

Classification Differences

One of the most significant differences is how devices are classified. The FDA uses a panel-based system with over 1,700 product codes, each pre-assigned to a class. If your device matches an existing product code, the class is already determined.

The EU MDR uses a rule-based system (22 rules in Annex VIII) that you apply based on your device's characteristics and intended purpose. This is more flexible but also more complex, as multiple rules can apply and you must take the highest resulting class.

Important: A device classified as Class II in the US is not necessarily Class IIa or IIb in Europe. Always classify independently under each system.

Clinical Evidence Requirements

This is where the two systems diverge most significantly:

FDA 510(k)

For most 510(k) submissions, clinical data is not required. The primary goal is to demonstrate substantial equivalence through:

• Comparison of intended use and technological characteristics
• Bench testing (performance data)
• Biocompatibility testing
• Literature review of predicate device history

Clinical data becomes more commonly required for higher-risk Class II devices and when performance cannot be adequately assessed through bench testing alone.

EU MDR

Under the EU MDR, a clinical evaluation is mandatory for all device classes. This must include:

• A systematic literature review
• Analysis of clinical experience from post-market surveillance
• For Class III and implantable devices: clinical investigations are generally expected unless justified by existing data
• Ongoing post-market clinical follow-up (PMCF)

The EU MDR places much greater emphasis on clinical evidence throughout the product lifecycle, not just at the point of market entry.

Post-Market Requirements

FDA

• Medical Device Reporting (MDR) for adverse events
• Establishment registration and device listing (annual)
• Corrections and removals (recalls)

EU MDR

• Post-Market Surveillance (PMS) system and plan
• Vigilance reporting (serious incidents, field safety corrective actions)
• Periodic Safety Update Report (PSUR) for Class IIb and III
• Post-Market Surveillance Report (PMSR) for Class I and IIa
• Post-Market Clinical Follow-up (PMCF) plan and report
• EUDAMED registration

The EU MDR post-market obligations are considerably more extensive and structured than the FDA requirements.

Practical Implications for Dual Submissions

If you plan to market your device in both the US and EU, consider these strategies:

1. Classify independently under both systems. Don’t assume equivalence.
2. Start with clinical evidence planning. If you need clinical data for EU MDR, that data can often support your FDA submission too. Plan studies to serve both pathways.
3. Build your QMS to cover both. ISO 13485 is recognized by both regions. Structure your quality system to meet FDA 21 CFR 820 and EU MDR Annex IX simultaneously.
4. Plan timelines carefully. FDA 510(k) is typically faster, but EU MDR may require a longer evidence-gathering phase. Start the EU process early.
5. Budget for Notified Body fees. Unlike the FDA (where you pay a user fee), Notified Bodies are commercial entities with their own fee structures, and capacity has been limited since MDR implementation.